Novel Biomarker that Discriminates Indolent from Aggressive Phenotype in African American Men
Prostate cancer exhibits the most striking racial disparity. African Americans are at 1.4 times higher risk of being diagnosed with prostate cancer than Caucasians. There is no race-specific biomarker that would provide information at the time of diagnosis if the tumor is treatable or has tendency to spread to other parts of body (metastasis) and become resistant to therapies. Serum-PSA as a disease type discriminating marker is reported to perform poorly in African-American men.
Hyposis: ROBO1 could act as a potential biomarker that would discriminate between primary and metastatic disease in African Americans, and possibly a therapeutic target to treat metastatic CaP in this population.